Zimmer Biomet Names CEO of Dental/Spine Spin-Off
Zimmer Biomet Names CEO of Dental/Spine Spin-Off
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that after an extensive search, Vafa Jamali has been appointed as CEO of "NewCo", the independent, publicly traded company that will be created by a previously announced spin off transaction, expected to close in mid-2022. NewCo will be comprised of Zimmer Biomet's current Spine and Dental businesses.
Mr. Jamali most recently served as the Chief Commercial Officer of Rockley Photonics, where he led commercial strategic planning for the early-stage integrated optics solutions provider. Prior to that, he was Senior Vice President and President of Respiratory, Gastrointestinal & Informatics (RGI) at Medtronic, responsible for the strategic direction, R&D, global execution and leadership of the $3 billion in annual revenue business that included 10,000 team members across four businesses and 14 manufacturing sites. During his tenure at Medtronic, he was also successful in significantly accelerating growth and expanding margins across his division within the company.
"Vafa's extensive knowledge and experience in building teams, developing long-term growth strategies, prioritizing resources, driving execution and delivering growth across the medical device industry make him the ideal leader to shape the direction of NewCo and move the business forward," said Bryan Hanson, President and CEO of Zimmer Biomet. "I look forward to partnering with Vafa – and the leadership team that he builds – through this important transition so we can position NewCo for maximum success."
"I'm so excited to join NewCo at this pivotal time in the company's creation," said Mr. Jamali. "This is a prime opportunity to leverage my experience in execution and value creation for NewCo. I am looking forward to working closely with the new team to develop and drive investment strategies and a plan for long-term growth in the Spine and Dental markets – all with a relentless focus on delivering for patients, customers, team members and our future shareholders."
With more than 25 years of experience in the medical device industry – including 20 years in executive leadership positions – Mr. Jamali has extensive knowledge in a variety of medical device specialties. Before leading the RGI business, he served as Senior Vice President and President of Early Technologies at Medtronic. Prior to Medtronic, he held leadership roles at Covidien, Cardinal Health, and Baxter. Mr. Jamali received his Bachelor of Commerce degree with distinction from the University of Alberta in Edmonton, Canada. He has completed a number of executive leadership programs, including the Harvard Executive Leadership Program in 2020. Mr. Jamali also serves on the Board of Directors for Baylis Medical, a manufacturer of innovative cardiology devices.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare and design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
(WARSAW, Ind., Feb. 16, 2021/PRNewswire/Source: Zimmer Biomet Holdings, Inc.)
You May Also Like
A new non-surgical treatment to lessen patient’s pain and get them back to their active lifestyles: Miller Orthopedic Specialists introduces MOS Regenerative Medicine Solutions, a non-surgical treatment that uses a patient’s own stem cells to promote healing within. MOS Regenerative Medicine Solutions has multiple types of treatments that... Read More
Driving Orthopaedic Procedure Costs Down: OIC Launches One Procedure, One Price(TM) Initiative: In orthopaedic procedures, commoditized implants are typically the most significant expense. Medical devices companies have put exorbitant price tags on implants and tools differentiated by sales and marketing expenses, not innovative technology... Read More
Syntellix Lauded by Frost & Sullivan for its Bioresorbable Orthopedic Implant: The innovation reduces surgical complications and time in the OR without any major changes to standard procedures - all while decreasing healthcare costs. The MAGNEZIX implant's unique capability of converting metal to bone makes it an ideal implant of the future ... Read More
Trauma Implants Market to Reach 10.14 Billion by 2026: The global Trauma Implants Market size is expected to reach USD 10.14 billion by 2026, exhibiting a CAGR of 4.3% during the forecast period. The increasing prevalence of sports injuries among children and teenagers will contribute significantly to the Trauma Implants Market share in the forthcoming years... Read More
The Coronavirus has increased the focus on healthcare and modern equipment: Globally, no sector has been placed under the magnifying glass more than the healthcare sector due to the Corona pandemic. Hospitals, outpatient clinics, practice-based physicians and care facilities have experienced a sudden increased demand for medical and laboratory technology... Read More